Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Pharmacist-Led Collaborative Care Model for Cardiometabolic Risk Reduction: A Case Study

A Pharmacist-Led Collaborative Care Model for Cardiometabolic Risk Reduction: A Case Study failure, and chronic kidney disease and in PWD at Case Presentation increased risk of ASCVD. However, these agents A 49-year-old uninsured African American remain underutilized, leaving many PWD at male with type 2 diabetes, receiving care at high risk for myocardial infarction, stroke, and CrossOver Healthcare Ministry, was referred cardiovascular death. to the PharmD clinic in August 2017 by his The ADA also recommends the use of PCC. He presented with a baseline A1C >9% multidisciplinary teams that draw from many and resistant hypertension. At the initial visit, health care professionals, including pharmacists the individual expressed a strong desire to lose (PharmD). Pharmacists manage medications weight and improve his health. His medical through collaborative practice agreements, state conditions included type 2 diabetes, heart failure protocols, or as recognized providers. Previous with improved ejection fraction (HFiEF) with evidence shows pharmacist-led interventions EF = 50%, resistant hypertension, obesity, and 14-21 improve clinical outcomes, including A1C. hyperlipidemia. However, no studies have examined whether Initial treatment for diabetes at presentation to the addition of pharmacists to the care team the PharmD clinic consisted of premixed insulin increases the prescribing of SGLT-2 inhibitors and 70/30 (70% insulin NPH/30% insulin regular), 34 GLP-1 receptor agonists http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png ADCES in Practice SAGE

A Pharmacist-Led Collaborative Care Model for Cardiometabolic Risk Reduction: A Case Study

Download PDF
4 pages

Loading next page...
 
/lp/sage/a-pharmacist-led-collaborative-care-model-for-cardiometabolic-risk-UhFrjkkZxT

References (31)

Publisher
SAGE
Copyright
© 2021 by the American Association of Diabetes Educators
ISSN
2633-559X
eISSN
2633-5603
DOI
10.1177/2633559X21994855
Publisher site
See Article on Publisher Site

Abstract

failure, and chronic kidney disease and in PWD at Case Presentation increased risk of ASCVD. However, these agents A 49-year-old uninsured African American remain underutilized, leaving many PWD at male with type 2 diabetes, receiving care at high risk for myocardial infarction, stroke, and CrossOver Healthcare Ministry, was referred cardiovascular death. to the PharmD clinic in August 2017 by his The ADA also recommends the use of PCC. He presented with a baseline A1C >9% multidisciplinary teams that draw from many and resistant hypertension. At the initial visit, health care professionals, including pharmacists the individual expressed a strong desire to lose (PharmD). Pharmacists manage medications weight and improve his health. His medical through collaborative practice agreements, state conditions included type 2 diabetes, heart failure protocols, or as recognized providers. Previous with improved ejection fraction (HFiEF) with evidence shows pharmacist-led interventions EF = 50%, resistant hypertension, obesity, and 14-21 improve clinical outcomes, including A1C. hyperlipidemia. However, no studies have examined whether Initial treatment for diabetes at presentation to the addition of pharmacists to the care team the PharmD clinic consisted of premixed insulin increases the prescribing of SGLT-2 inhibitors and 70/30 (70% insulin NPH/30% insulin regular), 34 GLP-1 receptor agonists

Journal

ADCES in Practice – SAGE

Published: Jan 1, 2021

There are no references for this article.